Patient compliance improves with twice-daily dosing

September 1, 2003

Fort Lauderdale, FL-A twice-daily dosing regimen of pemirolast potassium 0.1% ophthalmic solution (Alamast, Santen Inc., of Napa, CA, and Tampere, Finland) is as effective as the four-times-daily regimen of the drug for treating seasonal allergic conjunctivitis. The simpler dosing regimen may enhance patient compliance.